Review of periprosthetic osteolysis in total joint arthroplasty: An emphasis on host factors and future directions

Journal of Orthopaedic Research

Volumn 30, Issue 4, 2012, Pages 541-546

  Beck, Ryan T ^a   Illingworth, Kenneth D ^a   Saleh, Khaled J ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aseptic loosening; future directions; host factors; periprosthetic osteolysis; wear debris

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AM 162; BONE CEMENT; DENOSUMAB; ERYTHROMYCIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ARTHROPLASTY; ARTICLE; BODY MASS; BODY WEIGHT; BONE ATROPHY; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DIAGNOSTIC IMAGING; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOPROSTHESIS; ENDOPROSTHESIS LOOSENING; GENETIC SUSCEPTIBILITY; GENOTYPE; GOUT; HEREDITY; HUMAN; INFLAMMATION; MECHANICAL STRESS; MEDLINE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; PATHOPHYSIOLOGY; PERIPROSTHETIC OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTHESIS MATERIAL; PSORIATIC ARTHRITIS; RADIOGRAPHIC TEXTURE ANALYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; TOTAL HIP PROSTHESIS;

ARTHROPLASTY, REPLACEMENT; HUMANS; OSTEOLYSIS; PROSTHESIS FAILURE; REOPERATION;

EID: 84857030815     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21554     Document Type: Article

References (80)

1. Kurtz S, Ong K, Lau E, et al. 2007. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89: 780-785. (Pubitemid 46564282)
2. Harris WH,. 1995. The problem is osteolysis. Clin Orthop Relat Res 311: 46-53.
3. Desai MA, Bancroft LW,. 2008. The case. Diagnosis: periprosthetic osteolysis. Orthopedics 31 (518): 615-618.
4. Marshall A, Ries MD, Paprosky W,. 2008. How prevalent are implant wear and osteolysis, and how has the scope of osteolysis changed since 2000? J Am Acad Orthop Surg 16 (Suppl 1): S1-S6.
5. Baker PN, McMurtry IA, Chuter G, et al. 2010. THA with the ABG I prosthesis at 15 years. Excellent survival with minimal osteolysis. Clin Orthop Relat Res 468: 1855-1861.
6. Saleh KJ, Thongtrangan I, Schwarz EM,. 2004. Osteolysis: medical and surgical approaches. Clin Orthop Relat Res 427: 138-147. (Pubitemid 39362844)
7. Jacobs CA, Christensen CP, Greenwald AS, et al. 2007. Clinical performance of highly cross-linked polyethylenes in total hip arthroplasty. J Bone Joint Surg Am 89: 2779-2786. (Pubitemid 350230635)
8. Koreny T, Tunyogi-Csapo M, Gal I, et al. 2006. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 54: 3221-3232. (Pubitemid 44622093)
9. Beraudi A, Stea S, Cremonini S, et al. 2009. Assessment of five interleukins in human synovial fluid as possible markers for aseptic loosening of hip arthroplasty. Artif Organs 33: 538-543.
10. Yang SY, Yu H, Gong W, et al. 2007. Murine model of prosthesis failure for the long-term study of aseptic loosening. J Orthop Res 25: 603-611. (Pubitemid 46744725)
11. Qian Y, Zeng BF, Zhang XL, et al. 2008. Substance P stimulates production of interleukin 1beta and tumor necrosis factor alpha in fibroblasts from hip periprosthetic membrane. J Arthroplasty 23: 581-585.
12. Tashjian RZ, Lin C, Aswad B, et al. 2008. 11Beta-hydroxysteroid dehydrogenase type 1 expression in periprosthetic osteolysis. Orthopedics 31: 545.
13. St Pierre CA, Chan M, Iwakura Y, et al. 2010. Periprosthetic osteolysis: characterizing the innate immune response to titanium wear-particles. J Orthop Res 28: 1418-1424.
14. Talmo CT, Shanbhag AS, Rubash HE,. 2006. Nonsurgical management of osteolysis: challenges and opportunities. Clin Orthop Relat Res 453: 254-264. (Pubitemid 44900991)
15. Geng DC, Xu YZ, Yang HL, et al. 2010. Inhibition of titanium particle-induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630. J Biomed Mater Res A 95: 321-326.
16. Wang CT, Lin YT, Chiang BL, et al. 2010. Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31: 77-82.
17. Pearle AD, Crow MK, Rakshit DS, et al. 2007. Distinct inflammatory gene pathways induced by particles. Clin Orthop Relat Res 458: 194-201. (Pubitemid 46701377)
18. Purdue PE, Koulouvaris P, Nestor BJ, et al. 2006. The central role of wear debris in periprosthetic osteolysis. HSS J 2: 102-113. (Pubitemid 44328104)
19. Purdue PE, Koulouvaris P, Potter HG, et al. 2007. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454: 251-261. (Pubitemid 46074927)
20. Abu-Amer Y, Darwech I, Clohisy JC,. 2007. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9 (Suppl 1): S6.
21. D'Antonio JA, Manley MT, Capello WN, et al. 2005. Five-year experience with crossfire highly cross-linked polyethylene. Clin Orthop Relat Res 441: 143-150. (Pubitemid 44384216)
22. Dorr LD, Wan Z, Shahrdar C, et al. 2005. Clinical performance of a Durasul highly cross-linked polyethylene acetabular liner for total hip arthroplasty at 5 years. J Bone Joint Surg Am 87: 1816-1821. (Pubitemid 41061203)
23. McCalden RW, MacDonald SJ, Rorabeck CH, et al. 2009. Wear rate of highly cross-linked polyethylene in total hip arthroplasty. A randomized controlled trial. J Bone Joint Surg Am 91: 773-782.
24. Digas G, Karrholm J, Thanner J, et al. 2007. Five-year experience of highly cross-linked polyethylene in cemented and uncemented sockets: two randomized studies using radiostereometric analysis. Acta Orthop 78: 746-754. (Pubitemid 351185595)
25. Muratoglu OK, Bragdon CR, O'Connor DO, et al. 2001. A novel method of cross-linking ultra-high-molecular-weight polyethylene to improve wear, reduce oxidation, and retain mechanical properties. Recipient of the 1999 HAP Paul Award. J Arthroplasty 16: 149-160. (Pubitemid 32163841)
26. Kurtz SM, Gawel HA, Patel JD,. 2011. History and systematic review of wear and osteolysis outcomes for first-generation highly crosslinked polyethylene. Clin Orthop Relat Res 469: 2262-2277.
27. Thomas GE, Simpson DJ, Mehmood S, et al. 2011. The 7-year wear of highly cross-linked polyethylene in total hip arthroplasty: a double-blind, randomized controlled trial using radiostereometric analysis. J Bone Joint Surg Am 93: 716-722.
28. Ries MD, Scott ML, Jani S,. 2001. Relationship between gravimetric wear and particle generation in hip simulators: conventional compared with cross-linked polyethylene. J Bone Joint Surg Am 83-A (Suppl 2 Pt 2): 116-122. (Pubitemid 33070041)
29. Endo MM, Barbour PS, Barton DC, et al. 2001. Comparative wear and wear debris under three different counterface conditions of crosslinked and non-crosslinked ultra high molecular weight polyethylene. Biomed Mater Eng 11: 23-35. (Pubitemid 32151750)
30. Fisher J, McEwen HM, Tipper JL, et al. 2004. Wear, debris, and biologic activity of cross-linked polyethylene in the knee: benefits and potential concerns. Clin Orthop Relat Res 114-119. (Pubitemid 39506162)
31. Cuckler JM, Moore KD, Lombardi AV Jr, et al. 2004. Large versus small femoral heads in metal-on-metal total hip arthroplasty. J Arthroplasty 19: 41-44. (Pubitemid 39575826)
32. Cuckler JM,. 2005. The rationale for metal-on-metal total hip arthroplasty. Clin Orthop Relat Res 441: 132-136. (Pubitemid 44384214)
33. Long WT, Dorr LD, Gendelman V,. 2004. An American experience with metal-on-metal total hip arthroplasties: a 7-year follow-up study. J Arthroplasty 19: 29-34. (Pubitemid 39575824)
34. Migaud H, Putman S, Krantz N, et al. 2011. Cementless metal-on-metal versus ceramic-on-polyethylene hip arthroplasty in patients less than 50 years of age: a comparative study with 12 to 14-year follow-up. J Bone Joint Surg Am 93 (Suppl 2): 137-142.
35. Willert HG, Buchhorn GH, Fayyazi A, et al. 2005. Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg Am 87: 28-36. (Pubitemid 40094136)
36. Beaule PE, Campbell P, Mirra J, et al. 2001. Osteolysis in a cementless, second generation metal-on-metal hip replacement. Clin Orthop Relat Res 386: 159-165. (Pubitemid 32391289)
37. Beaule PE, Kim PR, Powell J, et al. 2011. A survey on the prevalence of pseudotumors with metal-on-metal hip resurfacing in Canadian academic centers. J Bone Joint Surg Am 93 (Suppl 2): 118-121.
38. D'Antonio J, Capello W, Manley M, et al. 2005. Alumina ceramic bearings for total hip arthroplasty: 5-year results of a prospective randomized study. Clin Orthop Relat Res 436: 164-171. (Pubitemid 40961043)
39. Hannouche D, Hamadouche M, Nizard R, et al. 2005. Ceramics in total hip replacement. Clin Orthop Relat Res 430: 62-71. (Pubitemid 40096133)
40. Clarke IC,. 1992. Role of ceramic implants. Design and clinical success with total hip prosthetic ceramic-to-ceramic bearings. Clin Orthop Relat Res 282: 19-30.
41. D'Antonio JA, Sutton K,. 2009. Ceramic materials as bearing surfaces for total hip arthroplasty. J Am Acad Orthop Surg 17: 63-68.
42. Walter WL, Yeung E, Esposito C,. 2010. A review of squeaking hips. J Am Acad Orthop Surg 18: 319-326.
43. Nercessian OA, Joshi RP, Martin G, et al. 2003. Influence of demographic and technical variables on the incidence of osteolysis in Charnley primary low-friction hip arthroplasty. J Arthroplasty 18: 631-637. (Pubitemid 37040360)
44. Roder C, Bach B, Berry DJ, et al. 2010. Obesity, age, sex, diagnosis, and fixation mode differently affect early cup failure in total hip arthroplasty: a matched case-control study of 4420 patients. J Bone Joint Surg Am 92: 1954-1963.
45. Schmalzried TP, Shepherd EF, Dorey FJ, et al. 2000. The John Charnley Award. Wear is a function of use, not time. Clin Orthop Relat Res 381: 36-46.
46. Berry DJ, Harmsen WS, Cabanela ME, et al. 2002. Twenty-five-year survivorship of 2000 consecutive primary Charnley total hip replacements: factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am 84-A: 171-177. (Pubitemid 37127476)
47. Fyda TM, Callaghan JJ, Olejniczak J, et al. 2002. Minimum 10-year follow-up of cemented total hip replacement in patients with osteonecrosis of the femoral head. Iowa Orthop J 22: 8-19.
48. Lubbeke A, Garavaglia G, Barea C, et al. 2010. Influence of obesity on femoral osteolysis 5 and 10 years following total hip arthroplasty. J Bone Joint Surg Am 92: 1964-1972.
49. Gallo J, Havranek V, Zapletalova J,. 2010. Risk factors for accelerated polyethylene wear and osteolysis in ABG I total hip arthroplasty. Int Orthop 34: 19-26.
50. Gallo J, Havranek V, Zapletalova J, et al. 2010. Male gender, Charnley class C, and severity of bone defects predict the risk for aseptic loosening in the cup of ABG I hip arthroplasty. BMC Musculoskelet Disord 11: 243.
51. Toh ML, Gonzales G, Koenders MI, et al. 2010. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 5: e13416.
52. Yu JJ, Ruddy MJ, Wong GC, et al. 2007. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 109: 3794-3802. (Pubitemid 46641730)
53. Gordon A, Greenfield EM, Eastell R, et al. 2010. Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli. J Orthop Res 28: 1127-1135.
54. Gallo J, Raska M, Mrazek F, et al. 2008. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res 57: 339-349.
55. Gallo J, Mrazek F, Petrek M,. 2009. Variation in cytokine genes can contribute to severity of acetabular osteolysis and risk for revision in patients with ABG 1 total hip arthroplasty: a genetic association study. BMC Med Genet 10: 109.
56. Gordon A, Kiss-Toth E, Stockley I, et al. 2008. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum 58: 3157-3165.
57. Shimizu S, Okuda N, Kato N, et al. 2010. Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages. Arthritis Rheum 62: 1329-1337.
58. Stulberg BN, Della Valle AG,. 2008. What are the guidelines for the surgical and nonsurgical treatment of periprosthetic osteolysis? J Am Acad Orthop Surg 16 (Suppl 1): S20-S25.
59. Vessely MB, Frick MA, Oakes D, et al. 2006. Magnetic resonance imaging with metal suppression for evaluation of periprosthetic osteolysis after total knee arthroplasty. J Arthroplasty 21: 826-831. (Pubitemid 44293234)
60. Cahir JG, Toms AP, Marshall TJ, et al. 2007. CT and MRI of hip arthroplasty. Clin Radiol 62: 1163-1171, discussion 72-73. (Pubitemid 350018625)
61. Howie DW, Neale SD, Stamenkov R, et al. 2007. Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am 89: 1818-1825. (Pubitemid 47229891)
62. Kress AM, Schmidt R, Vogel T, et al. 2011. Quantitative computed tomography-assisted osteodensitometry of the pelvis after press-fit cup fixation: a prospective 10-year follow-up. J Bone Joint Surg Am 93: 1152-1157.
63. Cook SD, Patron LP, Salkeld SL, et al. 2009. Correlation of computed tomography with histology in the assessment of periprosthetic defect healing. Clin Orthop Relat Res 467: 3213-3220.
64. Malchau H, Potter HG,. 2008. How are wear-related problems diagnosed and what forms of surveillance are necessary? J Am Acad Orthop Surg 16 (Suppl 1): S14-S19.
65. Walde TA, Weiland DE, Leung SB, et al. 2005. Comparison of CT, MRI, and radiographs in assessing pelvic osteolysis: a cadaveric study. Clin Orthop Relat Res 437: 138-144. (Pubitemid 41099080)
66. Schwarz EM, Campbell D, Totterman S, et al. 2003. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 21: 1049-1055. (Pubitemid 37322387)
67. Vandenbussche E, Saffarini M, Hansen U, et al. 2010. Measurement of femoral head penetration in polyethylene using a three-dimensional CT-scan technique. Acta Orthop 81: 563-569.
68. Looney RJ, Boyd A, Totterman S, et al. 2002. Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. Arthritis Res 4: 59-63. (Pubitemid 34100490)
69. Mumme T, Reinartz P, Alfer J, et al. 2005. Diagnostic values of positron emission tomography versus triple-phase bone scan in hip arthroplasty loosening. Arch Orthop Trauma Surg 125: 322-329. (Pubitemid 40895353)
70. Nixon M, Taylor G, Sheldon P, et al. 2007. Does bone quality predict loosening of cemented total hip replacements? J Bone Joint Surg Br 89: 1303-1308. (Pubitemid 350157310)
71. Wilkie JR, Giger ML, Chinander MR, et al. 2008. Temporal radiographic texture analysis in the detection of periprosthetic osteolysis. Med Phys 35: 377-387.
72. Smith LK, Cramp F, Palmer S, et al. 2010. Use of morphometry to quantify osteolysis after total hip arthroplasty. Clin Orthop Relat Res 468: 3077-3083.
73. Wilkie JR, Giger ML, Engh CA Sr, et al. 2008. Radiographic texture analysis in the characterization of trabecular patterns in periprosthetic osteolysis. Acad Radiol 15: 176-185.
74. Wu W, Zhang X, Zhang C, et al. 2009. Expansion of CD14+CD16+ peripheral monocytes among patients with aseptic loosening. Inflamm Res 58: 561-570.
75. Haynes DR, Atkins GJ, Loric M, et al. 1999. Bi-directional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone 25: 269-278. (Pubitemid 29406052)
76. Zhang P, Qin L,. 2010. Potential use of erythromycin to prevent and treat prosthetic failure. J Clin Pharmacol 50: 858-860.
77. Schwarz EM,. 2008. What potential biologic treatments are available for osteolysis? J Am Acad Orthop Surg 16 (Suppl 1): S72-S75.
78. Ren W, Zhang R, Wu B,. 2011. Effects of SU5416 and a vascular endothelial growth factor neutralizing antibody on wear debris-induced inflammatory osteolysis in a mouse model. J Inflamm Res 4: 29-38.
79. Ren W, Zhang R, Markel DC, et al. 2007. Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis. J Rheumatol 34: 27-35. (Pubitemid 46106559)
80. Schwarz EM, Ritchlin CT,. 2007. Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 (Suppl 1): S7.